104 related articles for article (PubMed ID: 11877751)
21. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
22. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
23. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
24. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters.
Stabin MG; Siegel JA; Sparks RB
Cancer Biother Radiopharm; 2002 Oct; 17(5):535-43. PubMed ID: 12470423
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.
Sgouros G
J Nucl Med; 1993 Apr; 34(4):689-94. PubMed ID: 8455089
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow dosimetry: regional variability of marrow-localizing antibody.
Sgouros G; Jureidini IM; Scott AM; Graham MC; Larson SM; Scheinberg DA
J Nucl Med; 1996 Apr; 37(4):695-8. PubMed ID: 8691269
[TBL] [Abstract][Full Text] [Related]
28. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
[TBL] [Abstract][Full Text] [Related]
29. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody.
Garkavij M; Tennvall J; Strand SE; Sjögren HO; JianQing C; Nilsson R; Isaksson M
J Nucl Med; 1997 Jun; 38(6):895-901. PubMed ID: 9189138
[TBL] [Abstract][Full Text] [Related]
30. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.
Shen S; DeNardo GL; Sgouros G; O'Donnell RT; DeNardo SJ
J Nucl Med; 1999 Dec; 40(12):2102-6. PubMed ID: 10616892
[TBL] [Abstract][Full Text] [Related]
31. The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
Örbom A; Eriksson SE; Elgström E; Ohlsson T; Nilsson R; Tennvall J; Strand SE
J Nucl Med; 2013 Aug; 54(8):1404-10. PubMed ID: 23804328
[TBL] [Abstract][Full Text] [Related]
32. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
[TBL] [Abstract][Full Text] [Related]
33. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
Juweid M; Sharkey RM; Siegel JA; Behr T; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5827s-5831s. PubMed ID: 7493354
[TBL] [Abstract][Full Text] [Related]
34. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
[TBL] [Abstract][Full Text] [Related]
35. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
Colnot DR; Ossenkoppele GJ; Roos JC; Quak JJ; de Bree R; Börjesson PK; Huijgens PC; Snow GB; van Dongen GA
Clin Cancer Res; 2002 Nov; 8(11):3401-6. PubMed ID: 12429627
[TBL] [Abstract][Full Text] [Related]
36. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
37. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
39. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
Breitz HB; Fisher DR; Wessels BW
J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab')2 fragments.
Buchegger F; Chalandon Y; Pèlegrin A; Hardman N; Mach JP
J Nucl Med; 1991 Jul; 32(7):1414-21. PubMed ID: 2066798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
